IL-32在病理性瘢痕基因治疗中的研究进展  

Research Progress of IL-32 Gene Therapy in Pathological Scars

作　　者：李小川[1] 张培华[2] 

机构地区：[1]广东医学院,广东湛江524023 [2]广东医学院附属医院整形外科,广东湛江524001

出　　处：《医学综述》2012年第9期1284-1286,共3页Medical Recapitulate

基　　金：2009年广东省自然科学基金(9151008002000010)

摘　　要：白细胞介素(IL)32是新近发现的炎性细胞因子,能诱生细胞因子的产生,且在调节细胞增殖与凋亡过程中有重要作用。瘢痕组织中成纤维细胞IL-32基因的蛋白表达水平明显低下,提示在瘢痕成纤维细胞中存在IL-32基因的缺失。随着基因治疗技术的日益成熟,以IL-32为目的基因导入到瘢痕成纤维细胞中来调控过度增生的成纤维细胞及减少胶原等大量细胞外基质的过度产生和沉积。现就IL-32的生物学特性及在病理性瘢痕中的作用及应用前景等进行综述,以期为以后的实验及临床作铺垫。Interleukin（IL）32 is a newly discovered inflammatory cytokine which can induce the production of cytokine playing an important role in regulation of cell proliferation and apoptosis.It is the significantly lower expression levels of IL-32 gene that prompt IL-32 gene deletion in scar fibroblasts.With increasingly sophisticated technology in gene therapy,we import IL-32 as the target gene into scar fibroblasts to regulate cell proliferation and apoptosis and reduce the large number of extracellular matrix collagen overproduction and deposition.Here is to make a review on the biological characteristics of IL-32 and the function and application prospects in pathological scars,for further lab and clinical research.

关 键 词：白细胞介素32 病理性瘢痕 成纤维细胞 基因治疗 

分 类 号：R622[医药卫生—整形外科]